Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Tislelizumab with or Without Transhepatic Arterial Embolization for Unresectable Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and High Tumor Burden: A Multicenter Retrospective Study

PURPOSE: The current therapeutic strategies for high-risk, unresectable hepatocellular carcinoma (HCC) patients demonstrate suboptimal outcomes. This study aimed to assess the clinical efficacy of the combined approach of hepatic arterial infusion chemotherapy (HAIC), lenvatinib, and tislelizumab, e...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Song, Shi, Feng, Wu, Zhiqiang, Wang, Liguang, Cai, Hongjie, Ma, Ping, Zhou, Yuanmin, Mai, Qicong, Wang, Fan, Tang, Shuangyan, Zhuang, Wenquan, Lai, Jiaming, Chen, Xiaoming, Chen, Huanwei, Guo, Wenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390715/
https://www.ncbi.nlm.nih.gov/pubmed/37533600
http://dx.doi.org/10.2147/JHC.S417550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390715/
https://www.ncbi.nlm.nih.gov/pubmed/37533600
http://dx.doi.org/10.2147/JHC.S417550

Ejemplares similares